Dupont Capital Management Corp lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 72.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,865 shares of the company’s stock after acquiring an additional 10,863 shares during the quarter. Dupont Capital Management Corp’s holdings in Myriad Genetics were worth $752,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in MYGN. Quantbot Technologies LP acquired a new stake in Myriad Genetics during the third quarter valued at $130,000. Quantamental Technologies LLC acquired a new stake in Myriad Genetics during the fourth quarter valued at $123,000. First Quadrant L P CA acquired a new stake in Myriad Genetics during the third quarter valued at $201,000. Ibex Investors LLC acquired a new stake in Myriad Genetics during the third quarter valued at $202,000. Finally, Parametrica Management Ltd acquired a new stake in Myriad Genetics during the third quarter valued at $204,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

MYGN opened at $30.18 on Thursday. The company has a current ratio of 2.97, a quick ratio of 2.68 and a debt-to-equity ratio of 0.26. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 25.15, a P/E/G ratio of 1.91 and a beta of 0.71. Myriad Genetics, Inc. has a 52-week low of $26.05 and a 52-week high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.34 by $0.04. The business had revenue of $216.80 million for the quarter, compared to the consensus estimate of $217.69 million. Myriad Genetics had a net margin of 3.25% and a return on equity of 9.79%. The company’s revenue was up 15.4% compared to the same quarter last year. During the same period last year, the firm posted $0.31 earnings per share. On average, research analysts anticipate that Myriad Genetics, Inc. will post 1.49 earnings per share for the current fiscal year.

Several research firms recently commented on MYGN. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research report on Tuesday, October 23rd. Deutsche Bank raised their price target on shares of Myriad Genetics from $37.00 to $43.00 and gave the company a “hold” rating in a research report on Monday, November 5th. Goldman Sachs Group upgraded shares of Myriad Genetics from a “sell” rating to a “neutral” rating and set a $32.72 price target on the stock in a research report on Sunday, December 9th. Cowen upgraded shares of Myriad Genetics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 4th. Finally, BidaskClub lowered shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $39.87.

WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/dupont-capital-management-corp-grows-stake-in-myriad-genetics-inc-mygn/2819389.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Read More: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.